Network meta-analysis for comparing treatment effects of multiple interventions: an introduction
- 839 Downloads
Systematic reviews and meta-analyses of randomized trials have long been important synthesis tools for guiding evidence-based medicine. More recently, network meta-analyses, an extension of traditional meta-analyses enabling the comparison of multiple interventions, use new statistical methods to incorporate clinical evidence from both direct and indirect treatment comparisons in a network of treatments and associated trials. There is a need to provide education to ensure that core methodological considerations underlying network meta-analyses are well understood by readers and researchers to maximize their ability to appropriately interpret findings and appraise validity. Network meta-analyses are highly informative for assessing the comparative effects of multiple competing interventions in clinical practice and are a valuable tool for health technology assessment and comparative effectiveness research.
KeywordsNetwork meta-analysis Mixed-treatment comparisons Multiple-treatment comparisons Evidence synthesis Systematic reviews
D.M. is funded by a University Research Chair, University of Ottawa; B.H. is a Canadian Institutes of Health Research DSEN (Drug Safety and Effectiveness Network) New Investigator; and C.C. is supported by the Canadian Institutes of Health Research Vanier Canada Graduate Scholarship Program.
Conflict of interest
The authors do not have any conflict of interest.
- 1.Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews of interventions. Wiley, ChichesterGoogle Scholar
- 14.Catalá-López F, Hutton B, Moher D (2014) The transitivity property across randomized controlled trials: if B is better than A, and C is better than B, will C be better than A? Rev Esp Cardiol. doi: 10.1016/j.recesp.2013.11.016
- 24.Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A (2012) Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 6:429–464PubMedPubMedCentralGoogle Scholar
- 25.Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al (2009) A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a cochrane overview. CMAJ 181:787–796. Erratum in: CMAJ 2010 182(8):806Google Scholar
- 26.Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441PubMedCrossRefGoogle Scholar
- 30.Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV et al (2011) Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev 2:CD008794Google Scholar
- 37.Thorlund K, Druyts E, Aviña-Zubieta JA, Wu P, Mills EJ (2013) Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 72:1524–1535PubMedCrossRefGoogle Scholar